Challenges in Developing Biosimilars

The biosimilars market is set to expand over the next decade and beyond as a result of two major factors: the impending patent expires on blockbuster biologics and the financial crisis that is driving payers to push for wider adoption of biosimilars to manage the escalating costs of healthcare. Although many companies are keen on getting a share in the biosimilars market given its promising outlook, bringing these complex molecules from bench to launch can be a challenge, not just during the development stage but also in terms of the manufacturing process involved. 

  • Equivalence of complex drug products
  • Biosimilar monoclonal antibodies
  • Economic aspect towards biosimilars
  • Advertising, promotion and labeling essentials
  • Drug Safety essentials
  • Early clinical development essentials
  • Late clinical development essentials
  • Current concepts of drugs and biologics
  • Unique considerations for biologics
  • Comparability for Biologics

Related Conference of Challenges in Developing Biosimilars

February 28-March 01, 2019 ANA Crowne Plaza |

Global Pharmaceutical and Pharma Industry Conference

Osaka, Japan
March 18-19, 2019

13th International Conference on Biosimilars and Biologics

Amsterdam | Netherlands
July 26-27, 2019

13th Asian Biologics and Biosimilars Congress

Mercure Albert Park | Melbourne, Australia

Challenges in Developing Biosimilars Conference Speakers

Recommended Sessions

Related Journals

Are you interested in